The estimated Net Worth of Partners L P/Ilbiotechnolog... is at least $33.5 Million dollars as of 3 December 2013. Partners Ilbiotechnolog owns over 189,800 units of Rigel Pharmaceuticals stock worth over $16,237,325 and over the last 12 years Partners sold RIGL stock worth over $17,255,926.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Partners Ilbiotechnolog RIGL stock SEC Form 4 insiders trading
Partners has made over 10 trades of the Rigel Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Partners bought 189,800 units of RIGL stock worth $950,898 on 3 December 2013.
The largest trade Partners's ever made was buying 1,289,354 units of Rigel Pharmaceuticals stock on 8 October 2013 worth over $6,885,150. On average, Partners trades about 328,564 units every 36 days since 2012. As of 3 December 2013 Partners still owns at least 1,251,914 units of Rigel Pharmaceuticals stock.
You can see the complete history of Partners Ilbiotechnolog stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Rigel Pharmaceuticals
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.
What does Rigel Pharmaceuticals do?
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
What does Rigel Pharmaceuticals's logo look like?
Complete history of Partners Ilbiotechnolog stock trades at ChemoCentryx Inc, Ligand Pharmaceuticals, and Rigel Pharmaceuticals
Rigel Pharmaceuticals executives and stock owners
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include:
-
David A. Santos,
Exec. VP & Chief Commercial Officer -
Raul R. Rodriguez,
Pres, CEO & Director -
Dolly A. Vance,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Dr. Wolfgang Dummer M.D., Ph.D.,
Exec. VP & Chief Medical Officer -
Dean L. Schorno CPA,
Exec. VP & CFO -
Julie Patel,
Sr. VP of HR -
Tarek Sallam,
VP of Marketing -
Dr. Esteban S. Masuda,
Exec. VP of Research -
Joseph Lasaga,
Sr. VP of Corp. Devel. -
Gary A Lyons,
-
Brian L. Kotzin,
-
Jane Wasman,
-
Kamil Ali Jackson,
-
Donald G Payan,
Executive V.P. and CSO -
Peter S Ringrose,
Director -
Keith Katkin,
Director -
Ryan D Maynard,
VP Finance, Acting CFO -
Esteban Masuda,
Sr. VP Research -
Walter H Moos,
-
Bradford S Goodwin,
Director -
Stephen A Sherwin,
Director -
Eldon C. Iii Mayer,
EVP & Chief Commercial Officer -
James H Welch,
VP, CFO and Corp Secretary -
Alan D Frazier,
Director -
Elliot B Grossbard,
Sr VP of Med Development -
Anthony Gregg Lapointe,
-
Nelson Cabatuan,
VP,Finance & Princ.Acctg. Off. -
Stacy Markel,
EVP Human Resources -
Joseph Lasaga,
Sr.VP Bus.Dev.Alliance Mgmt. -
Anne Marie Duliege,
EVP & Chief Medical Officer -
Partners Ii Incalta Biophar...,
-
Nicholas J Iii Simon,
Director -
Bioventures Iii Qp Lpmpm Bi...,
-
Lukegadicke Ansbert Evnin,
-
Dennis Henner,
Director -
Jeanalta Partnersalta Calif...,
-
Nicholas Galakatos,
10% owner -
Michael Steinmetz,
10% owner -
Partners Ii Incalta Biophar...,
-
Ansbert Gadicke,
10% owner -
Luke Evnin,
10% owner -
Bioequities Master Fund Lpm...,
-
Healthcare Iv Lpfhm Iv Lpfh...,
-
Lisa Rojkjaer,
EVP, Chief Medical Officer -
James M Gower,
CEO and Chairman of the Board -
Partners L P/Ilbiotechnolog...,
-
Partners L P/Ilbiotechnolog...,
-
Hollings Renton,
Director -
James Edeerfield Capital Lp...,
-
James Edeerfield Capital Lp...,
-
Jean Deleage,
Director -
Robin D G Cooper,
Sr. V.P. Pharmaceutical Scs. -
David A Santos,
EVP, Chief Commercial Officer -
Wolfgang Dummer,
EVP & CMO -
Alison L. Hannah,
-
Dean L Schorno,
EVP & Chief Financial Officer -
Dolly Vance,
EVP Corp. Affairs, G.C., Sect. -
Raymond J. Furey,
EVP, GC, CCO & Corp Sec